GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (FRA:R9Z) » Definitions » Inventories, Finished Goods

ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z) Inventories, Finished Goods : €0.00 Mil (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is ImmuneOnco Biopharmaceuticals (Shanghai) Inventories, Finished Goods?


ImmuneOnco Biopharmaceuticals (Shanghai) Inventories, Finished Goods Historical Data

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuneOnco Biopharmaceuticals (Shanghai) Inventories, Finished Goods Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Inventories, Finished Goods
- - - -

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Inventories, Finished Goods Get a 7-Day Free Trial - - - - -

ImmuneOnco Biopharmaceuticals (Shanghai) Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.


ImmuneOnco Biopharmaceuticals (Shanghai) Business Description

Traded in Other Exchanges
Address
1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.

ImmuneOnco Biopharmaceuticals (Shanghai) Headlines

No Headlines